Benchmark Reaffirms “Buy” Rating for Humacyte (NASDAQ:HUMA)

Humacyte (NASDAQ:HUMA)‘s stock had its “buy” rating reaffirmed by investment analysts at Benchmark in a research report issued on Thursday,Benzinga reports.

Several other equities research analysts also recently commented on HUMA. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price (up previously from $12.00) on shares of Humacyte in a research note on Friday, December 20th. D. Boral Capital restated a “buy” rating and issued a $25.00 price objective on shares of Humacyte in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Humacyte presently has a consensus rating of “Buy” and an average target price of $13.71.

Humacyte Price Performance

Shares of HUMA stock opened at $3.40 on Thursday. The stock has a market cap of $427.92 million, a PE ratio of -2.54 and a beta of 1.30. The stock has a 50-day moving average of $4.36 and a 200-day moving average of $4.96. Humacyte has a one year low of $2.81 and a one year high of $9.97.

Institutional Investors Weigh In On Humacyte

Institutional investors have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. raised its stake in shares of Humacyte by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 22,955 shares of the company’s stock valued at $125,000 after purchasing an additional 8,965 shares during the period. Concurrent Investment Advisors LLC acquired a new stake in Humacyte in the 3rd quarter valued at approximately $75,000. Victory Capital Management Inc. lifted its stake in Humacyte by 551.6% in the 3rd quarter. Victory Capital Management Inc. now owns 76,896 shares of the company’s stock valued at $418,000 after acquiring an additional 65,095 shares in the last quarter. Thrivent Financial for Lutherans acquired a new position in Humacyte during the 3rd quarter worth approximately $712,000. Finally, Intech Investment Management LLC acquired a new position in Humacyte during the 3rd quarter worth approximately $232,000. 44.71% of the stock is owned by institutional investors.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.